303175-44-2

Basic information

• Product Name: 2-(2-CHLORO-4-IODOPHENYLAMINO)-3,4-DIFLUOROBENZOIC ACID
• Synonyms: 2-(2-CHLORO-4-IODOPHENYLAMINO)-3,4-DIFLUOROBENZOIC ACID;3,4-difluoro-2-(2-chloro-4-iodophenylaMino)-benzoic acid
• CAS NO: 303175-44-2
• Molecular Formula: C₁₃H₇ClF₂INO₂
• Molecular Weight: 409.5544564
• Product Categories: Chemical Amines;Amines;Aromatics
• Mol File: 303175-44-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 230-231 °C
• Boiling Point: 401.451°C at 760 mmHg
• Flash Point: 196.591°C
• Appearance: /
• Density: 1.946g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.689
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.25±0.36(Predicted)
• CAS DataBase Reference: 2-(2-CHLORO-4-IODOPHENYLAMINO)-3,4-DIFLUOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-CHLORO-4-IODOPHENYLAMINO)-3,4-DIFLUOROBENZOIC ACID(303175-44-2)
• EPA Substance Registry System: 2-(2-CHLORO-4-IODOPHENYLAMINO)-3,4-DIFLUOROBENZOIC ACID(303175-44-2)

Safety Data

• Hazardous Substances Data: 303175-44-2(Hazardous Substances Data)

Usage

Description

2-(2-Chloro-4-iodophenylamino)-3,4-difluorobenzoic acid, with the CAS number 303175-44-2, is a light-brown solid compound that is useful in organic synthesis. It is characterized by the presence of a chloro and iodophenylamino group attached to a difluorobenzoic acid backbone, which contributes to its unique chemical properties and potential applications.

Uses

Used in Organic Synthesis:
2-(2-Chloro-4-iodophenylamino)-3,4-difluorobenzoic acid is used as a synthetic intermediate for the production of various organic compounds. Its unique structure allows it to be a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(2-Chloro-4-iodophenylamino)-3,4-difluorobenzoic acid is used as a key component in the development of new drugs. Its chemical properties enable it to be modified and combined with other molecules to create potential therapeutic agents with novel mechanisms of action.
Used in Agrochemical Industry:
2-(2-Chloro-4-iodophenylamino)-3,4-difluorobenzoic acid is also utilized in the agrochemical industry for the synthesis of new pesticides and herbicides. Its unique structure can be tailored to target specific pests or weeds, leading to more effective and environmentally friendly solutions for crop protection.
Used in Specialty Chemicals:
In the specialty chemicals sector, 2-(2-Chloro-4-iodophenylamino)-3,4-difluorobenzoic acid is employed as a raw material for the production of various high-value chemicals. Its versatility and unique properties make it suitable for applications in materials science, dyes, and other specialized fields.

InChI:InChI=1/C13H7ClF2INO2/c14-8-5-6(17)1-4-10(8)18-12-7(13(19)20)2-3-9(15)11(12)16/h1-5,18H,(H,19,20)

Upstream product

• 42016-93-3 2-chloro-4-iodoaniline 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 

Downstream Products

• 212631-79-3 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide 
• 391212-15-0 2-(2-Chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid pentafluorophenyl ester 

Relevant articles and documents

Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model

Antiviral therapies against influenza are required, especially for high-risk patients, severe influenza and in case of highly pathogenic influenza virus (IV) strains. However, currently, licensed drugs that target the virus directly are not very effective and often lead to the development of resistant IV variants. This may be overcome by targeting host cell factors that are required for IV propagation. IV induces a variety of host cell signaling cascades, such as the Raf/MEK/ERK kinase pathway. The activation of this pathway is necessary for IV propagation. MEK-inhibitors block the activation of the pathway on the bottleneck of the signaling cascade leading to impaired virus propagation. In the present study, we aimed to compare the antiviral potency and bioavailability of the MEK-inhibitor CI-1040 versus its major active metabolite ATR-002, in vitro as well as in the mouse model. In cell culture assays, an approximately 10-fold higher concentration of ATR-002 is required to generate the same antiviral activity as for CI-1040. Interestingly, we observed that considerably lower concentrations of ATR-002 were required to achieve a reduction of the viral load in vivo. Pharmacokinetic studies with ATR-002 and CI-1040 in mice have found the Cmax and AUC to be far higher for ATR-002 than for CI-1040. Our results thereby demonstrate the in vivo superiority of the active metabolite ATR-002 over CI-1040 as an antiviral agent despite its weaker cell membrane permeability. Therefore, ATR-002 is an attractive candidate for development as an efficient antiviral agent, especially given the fact that a treatment based on cellular pathway inhibition would be far less likely to lead to viral drug resistance.

Improved experimental procedure for the synthesis of the potent MEK inhibitor PD184352

An improved synthesis of the potent MEK inhibitor PD184352 (2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide)) is herein reported. This new and reproducible protocol provides a simple and efficient way of generating gram quantities of PD184352 with minimal purification. Copyright Taylor & Francis, Inc.

N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.